

UROFAIR 2019 – ORAL ABSTRACTS

Guidelines for Oral Presentation (Clinical Urology and Translational Research):

1. Presentation Duration and Reporting Time

- Presentations are scheduled for 6th April 2019, from 16:00 hrs to 18:00 hrs at the following rooms:
 - Clinical Urology - Oral Abstract: Grand Ballroom, Level 3
 - Translational Research – Oral Abstract: Grand Salon 1, Level 2
- Please see below for the Oral Abstract program schedule. All authors must take note of their presentation timing. You must report to the room at least **15 minutes** before your presentation.
- You will get strictly **8 minutes** for presentation + **2 minutes** for Questions and answers.
- Please email your presentations to sanjana@globewerks.com latest by 1st April to confirm your presentation.

2. Presentation Specifications

Software: Microsoft Power Point 2007 and subsequent versions.

- The format of the slides should be in Microsoft Power Point (.ppt or .pptx). Please save your presentation by abstract number and family name e.g. "C-10001-Tan.ppt".
- Use screen aspect ratio of 16:9 (widescreen).
- **Suggested fonts:** Arial or Times New Roman.
- **Images in your presentation:** It is preferable that the images are JPG format. The image resolution must not exceed 1024 x 768 pixels (width by height).
- **Video Formats will be accepted:** WMV, AVI or MP4

6th April 2019 (Saturday) – Clinical Urology

Time	Abstract ID	Category	Title	Author	Country
1605 - 1615	C-10032	Education	Psychological Morbidity And Learning Styles In Medical Students Rotating Through Urology	Ziting WANG	Singapore
1616 - 1626	C-10120	Education	Assessment Of Construct Validity Of Virtual Reality TURP Simulator	Ee Jean LIM	Singapore
1627 - 1637	C-10121	Incontinence	The Clinical Application Of A Minimally Invasive Non-Surgical Treatment For Stress Urinary Incontinence (SUI)	Jin YONG	Singapore
1638 - 1648	C-10010	Prostate Cancer	The Use Of Tissue Fiducial Markers (Traceit) To Improve The Accuracy Of Post-Prostatectomy Radiotherapy	Michael CHAO	Australia
1649 - 1659	C-10106	Prostate Cancer	68Ga PSMA PET/CT Detects Lesions “Invisible” On Multiparametric MRI; Single Centre Comparative Analysis With Whole Gland Histopathology As Gold Standard.	Dale WOOD	Australia
1700 - 1710	C-10156	Prostate Cancer	Initial Patient-Reported Outcomes Of Neoadjuvant Apalutamide (ARN-509) And Radical Prostatectomy In Treatment Of Intermediate To High Risk Prostate Cancer (NEAR) Trial – A Phase II Trial	Xin Yan YANG	Singapore
1711 - 1721	C-10162	Prostate Cancer	Neoadjuvant Apalutamide (ARN-509) And Radical Prostatectomy In Treatment Of Intermediate To High Risk Prostate Cancer (NEAR) Phase II Trial –Initial Oncological Outcomes	Xin Yan YANG	Singapore
1722 - 1732	C-10163	Prostate Cancer	Comparison Of PSMA-PET To mpMRI To Accurately Identify Primary Prostate Lesions In A Radical Prostatectomy Cohort	Hassanbhai Daneesh HUNED	Singapore
1733 - 1743	C-10077	Stone	Endoscopic Combined Intrarenal Surgery Versus Percutaneous Nephrolithotomy For Renal Stones Management: A Meta-Analysis	Eko Indra PRADONO	Indonesia

6th April 2019 (Saturday) – Translational Research

Time	Abstract ID	Category	Title	Author	Country
1605 - 1615	T-10037	Miscellaneous	Correlation Between Maternind-Like Domain Containing 1 (MAMLD1) Gene Mutation With Hypospadias Incidence	Safendra SIREGAR	Indonesia
1616 - 1626	T-10096	Miscellaneous	Promoter Polymorphism In Natural Resistance-Associated Macrophage Protein 1 (NRAMP1)	Yew Koon LIM	Singapore
1627 - 1637	T-10154	Miscellaneous	Negative Pressure Drains And Bladder Repair: An Ex-Vivo Ovine Model	Michael O'HALLORAN	Australia
1638 - 1648	T-10014	Prostate Cancer	Interim Analysis Of An International Multi-Centre Study Of AR-V7 In Asian Metastatic Castration-Resistant Prostate Cancer (MCRPC) Patients	Ravindran KANESVARAN	Singapore
1649 - 1659	T-10097	Bladder Cancer	Bladder Cancer Derived Extracellular Vesicles And Immune Activation	Sin Mun THAM	Singapore
1700 - 1710	T-10134	Bladder Cancer	Predicting Patient's Response To BCG Immunotherapy With The Aid Of DNA Methylation Status	Ziting WANG	Singapore
1711 - 1721	T-10141	Bladder Cancer	Polymorphism In Autophagy Gene ATG2B Is Not Associated With Recurrence Of Bladder Cancer After Bacillus Calmette-Guerin (BCG) Immunotherapy In Chinese Population.	Zhijiang ZANG	Singapore